

AUTHOR INDEX FOR VOLUME 26

A

- Albengres, Edith.** See *Urien, Riant, Brioude, and Tillement*, 322
Albuquerque, E. X. See *Aracava, Ikeda, Daly, and Brooks*, 304
 See *Ikeda, Aronstam, Daly, and Aracava*, 293
Ambler, S. Kelly, Brown, R. Dale, and Taylor, Palmer. The Relationship between Phosphatidylinositol Metabolism and Mobilization of Intracellular Calcium Elicited by α_1 -Adrenergic Receptor Stimulation in BC3H-1 Muscle Cells, 405
Aracava, Y. Ikeda, S. R., Daly, J. W., Brookes, N., and Albuquerque, E. X. Interactions of Bupivacaine with Ionic Channels of the Nicotinic Receptor: Analysis of Single-Channel Currents, 304
 See *Ikeda, Aronstam, Daly, and Albuquerque*, 293
Aronstam, R. S. See *Ikeda, S. R., Daly, J. W., Aracava, Y., and Albuquerque, E. X.*, 293
Aub, Debra L. See *Putney, McKinney, and Leslie*, 261

B

- Bachur, Nicholas R.** See *Gutierrez, Fox, and Mossoba*, 582
Bagley, Jerome R. See *Jordan, Lieberman, Cormier, Koch, and Ruenitz*, 272
Baker, James A. See *Jaques, Tobes, Sisson, and Wieland*, 539
Basker, K. M. See *Sultatos, Shao, and Murphy*, 99
Beaujouan, J. C., Torrens, Y., Viger, A., and Glowinski, J. A. New Type of Tachykinin Binding Site in the Rat Brain Characterized by Specific Binding of a Labeled Eledoisin Derivative, 248
Belinsky, Steven A., Kauffman, Frederick C., and Thurman, Ronald G. Reducing Equivalents for Mixed Function Oxidation in Periportal and Pericentral Regions of the Liver Lobule in Perfused Livers from Normal and Phenobarbital-Treated Rats, 574
Beuzard, Y. See *Garel, Domenget, Galacteros, and Martin-Caburi*, 559
Blanchard, S. G. See *Chang and Cuatrecasas*, 484
Blaustein, Robert O. See *Javitch and Snyder*, 35
Bockaert, Joël, Cantau, Bernard, and Sebben-Perez, Michèle. Hormonal Inhibition of Adenylate Cyclase: a Crucial Role for Mg^{2+} , 180
Bolger, Michael B., Dionne, Vincent, Chrivia, John, Johnson, David A., and Taylor, Palmer. Interaction of a Fluorescent Acylcholine with the Nicotinic Acetylcholine Receptor and Acetylcholinesterase, 57
Brioude, Robert. See *Urien, Riant, Albengres, and Tillement*, 322
Brookes, N. See *Aracava, Ikeda, Daly, and Albuquerque*, 304
Brown, Joan Heller. See *Masters and Harden*, 149
Brown, R. Dale. See *Ambler and Taylor*, 405
Burk, Raymond F. See *Krieter, Ziegler, and Hill*, 122
Butlen, Daniel. See *Guillon and Rajerison*, 241

C

- Cantau, Bernard.** See *Bockaert and Sebben-Perez*, 180
Cantoni, Orazio, Christie, Nelwyn T., Swann, Allan, Drath, David B., and Costa, Max. Mechanism of $HgCl_2$ Cytotoxicity in Cultured Mammalian Cells, 360
Caron, Marc G. See *Dickinson, Leeb-Lundberg, Heald, Wikberg, DeBernardis, and Lefkowitz*, 187
Chang, K.-J., Blanchard, S. G., and Cuatrecasas, P. Benzomorphinan Sites Are Ligand Recognition Sites of Putative ϵ -Receptors, 484
Chao, Sheng-Hao, Suzuki, Yasuhiro, Zysk, John R., and Cheung, Wai Yiu. Activation of Calmodulin by Various Metal Cations as a Function of Ionic Radius, 75
Cheung, Wai Yiu. See *Chao, Suzuki, and Zysk*, 75
Chou, Ting-Chao, Lopez, Carlos, Colacino, Joseph M., Fein-

- berg, Aaron, Watanabe, Kyoichi A., Fox, Jack J., and Philips, Frederick S.** Metabolic Competition Studies of 2'-Fluoro-5-iodo-1- β -D-arabinofuranosylcytosine in Vero Cells and Herpes Simplex Type 1-Infected Vero Cells, 587
Christie, Nelwyn T. See *Cantoni, Swann, Drath, and Costa*, 360
Chrivia, John. See *Bolger, Dionne, Johnson, and Taylor*, 57
Colacino, Joseph M. See *Chou, Lopez, Feinberg, Watanabe, Fox, and Philips*, 587
Collins, Sheila, and Marletta, Michael A. Carcinogen-Binding Proteins: High-Affinity Binding Sites for Benzo[a]pyrene in Mouse Liver Distinct from the Ah Receptor, 353
Cooper, Dermot M. F. See *Sadler and Maller*, 526
Corbett, Michael D. See *Doerge*, 348
Cormier, Ethel. See *Jordan, Lieberman, Koch, Bagley, and Ruenitz*, 272
Costa, Erminio. See *Quach, Tang, Kageyama, Mocchetti, Guidotti, Meek, and Schwartz*, 255
Costa, Max. See *Cantoni, Christie, Swann, and Drath*, 360
Cuatrecasas, P. See *Chang and Blanchard*, 484

D

- Dahlbom, Richard.** See *Ringdahl, Resul, Ehlert, and Jensen*, 170
Daly, J. W. See *Aracava, Ikeda, Brookes, and Albuquerque*, 304
 See *Ikeda, Aronstam, Aracava, and Albuquerque*, 293
Das, Mukul. See *Marnett, Siedlik, Ochs, Pagels, Honn, Warnock, Tainer, and Eling*, 328
DeBernardis, John F. See *Dickinson, Leeb-Lundberg, Heald, Wikberg, Caron, and Lefkowitz*, 187
De Clercq, Erik. See *Yokota, Konno, and Shigeta*, 376
De Léan, André, Ong, Huy, Gutkowska, Jolanta, Schiller, Peter W., and McNicoll, Normand. Evidence for Agonist-Induced Interaction of Angiotensin Receptor with a Guanine Nucleotide-Binding Protein in Bovine Adrenal Zona Glomerulosa, 498
 See *Wreggett*, 214
Dickinson, Kenneth E. J., Leeb-Lundberg, L. M. Fredrik, Heald, Sarah L., Wikberg, Jarl E. S., DeBernardis, John F., Caron, Marc G., and Lefkowitz, Robert J. Photoaffinity Cross-Linking of a Radiolabeled Probe, ^{125}I -A55453, into α_1 -Adrenergic Receptors, 187
Dionne, Vincent. See *Bolger, Chrivia, Johnson, and Taylor*, 57
Doerge, Daniel R., and Corbett, Michael D. Hydroperoxyflavin-Mediated Oxidations of Organosulfur Compounds: Model Studies for the Flavin Monooxygenase, 348
Domenget, C. See *Garel, Galacteros, Martin-Caburi, and Beuzard*, 559
Doss, Robert C. See *Waldo, Perkins, and Harden*, 424
Drath, David B. See *Cantoni, Christie, Swann, and Costa*, 360
Duax, W. L., Swenson, D. C., Strong, P. D., Korach, K. S., McLachlan, J., and Metzler, M. Molecular Structures of Metabolites and Analogues of Diethylstilbestrol and Their Relationship to Receptor Binding and Biological Activity, 520

E

- Eaton, David L.** See *Woods and Lukens*, 336
Eddy, Barbara. See *Venter, Horne, Greguski, and Fraser*, 196
Egan, E. See *Kufe, Munroe, Egan, and Spriggs*, 128
Ehlert, Frederick J. See *Ringdahl, Resul, Jenden, and Dahlbom*, 170
Eling, Thomas E. See *Marnett, Siedlik, Ochs, Pagels, Das, Honn, Warnock, and Tainer*, 328
Evans, Tony, Smith, McHardy M., Tanner, Laura I., and Harden, T. Kendall. Muscarinic Cholinergic Receptors of Two Cell Lines That Regulate Cyclic AMP Metabolism by Different Molecular Mechanisms, 395

F

- Feinberg, Aaron** See *Chou, Lopez, Colacino, Watanabe, Fox, and Philips*, 587
- Fishman, Peter H.** See *Zaremba*, 206
- Fleming, Richard M.** See *Howlett*, 532
- Fox, Bonnie M.** See *Gutierrez, Mossoba, and Bachur*, 582
- Fox, Jack J.** See *Chou, Lopez, Colacino, Feinberg, Watanabe, and Philips*, 587
- Fox, Richard M., Tripp, Edith H., and Taylor, Ian W.** Analytical DNA Flow Cytometric Analysis of Deoxyadenosine Toxicity in Cultured Human Leukemic Lymphoblasts, 388
- Fraser, Claire M.** See *Venter, Horne, Eddy, and Greguski*, 196
- Frazer, Alan.** See *Sills and Wolfe*, 10
- Frelin, Christian, Vigne, Paul, Schweitz, Hugues, and Lazdunski, Michel.** The Interaction of Sea Anemone and Scorpion Neurotoxins with Tetrodotoxin-Resistant Na⁺ Channels in Other Excitable and Non-excitable Cells, 70

G

- Galacteros, F.** See *Garel, Domenget, Martin-Caburi, and Beuzard*, 559
- Garel, M. C., Domenget, C., Galacteros, F., Martin-Caburi, J., and Beuzard, Y.** Inhibition of Erythrocyte Sickling by Thiol Reagents, 559
- Gasiewicz, Thomas A., and Rucci, George.** Cytosolic Receptor for 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin: Evidence for a Homologous Nature among Various Mammalian Species, 90
- Glazer, Robert I., and Knode, Marian C.** 1- β -D-Arabinosyl-5-azacytosine: Cytocidal Activity and Effects on the Synthesis and Methylation of DNA in Human Colon Carcinoma Cells, 381
- Glowinski, J.** See *Beaujouan, Torrens, and Viger*, 248
- Goldstein, Dora B.** See *Perlman*, 83
- See *Perlman*, 547
- Gonzalez, Frank J., Tukey, Robert H., and Nebert, Daniel W.** Structural Gene Products of the *Ah* Locus: Transcriptional Regulation of Cytochrome P₁-450 and P₃-450 mRNA Levels by 3-Methylcholanthrene, 117
- Greguski, Roger.** See *Venter, Horne, Eddy, and Fraser*, 196
- Guidotti, Alessandro.** See *Quach, Tang, Kageyama, Mocchetti, Meek, Costa, and Schwartz*, 255
- Guillon, Gilles, Butlen, Daniel, and Rajerison, Rabary.** Evidence for Two Molecular Forms of Solubilized Vasopressin Receptors in Rat Kidney Membranes: Regulation by Guanyl Nucleotides, 241
- Gutierrez, Peter L., Fox, Bonnie M., Mossoba, Magdi M., and Bachur, Nicholas R.** Free Radicals in Quinone-Containing Antitumor Agents: Electrochemical Reduction of Diaziquone (2,5-Diaziridine-3,6-bis(carboethoxyamino)-1,4-benzoquinone) and Two Analogues, 582
- Gutkowska, Jolanta.** See *De Léan, Ong, Schiller, and McNicoll*, 498

H

- Hancock, Arthur A., and Marsh, Catherine L.** Distinctions between Ligand-Binding Sites for [³H]Dopamine and D₂ Dopaminergic Receptors Characterized with [³H]Spiroperidol, 439
- Harden, T. Kendall.** See *Evans, Smith, and Tanner*, 395
- See *Masters and Brown*, 149
- See *Waldo, Doss, and Perkins*, 424
- Haynes, Laurence W., Smith, Margaret E., and Li, Choh Hao.** Structural Requirements and Species Specificity of the Inhibition by β -Endorphin of Heavy Acetylcholinesterase from Vertebrate Skeletal Muscle, 45
- Heald, Sarah L.** See *Dickinson, Leeb-Lundberg, Wikberg, DeBernardis, Caron, and Lefkowitz*, 187
- Herrick, David, and Kufe, Donald W.** Lethality Associated with Incorporation of 5-Fluorouracil into Preribosomal RNA, 135
- See *Kufe, Munroe, Egan, and Spriggs*, 128
- Hill, Kristina E.** See *Krieter, Ziegler, and Burk*, 122
- Hinson, J. A.** See *Mulder, Kadlubar, and Mays*, 342

- Holý, Antonin.** See *Schanche, Schanche, Ueland, and Votruba*, 553
- Honn, Kenneth V.** See *Marnett, Siedlik, Ochs, Pagels, Das, Warnock, Tainer, and Eling*, 328
- Horne, Peter.** See *Venter, Eddy, Greguski, and Fraser*, 196
- Howlett, Allyn C., and Fleming, Richard M.** Cannabinoid Inhibition of Adenylate Cyclase: Pharmacology of the Response in Neuroblastoma Cell Membranes, 532
- Hughes, Helen.** See *Smith and Mitchell*, 112

I

- Ikeda, S. R., Aronstam, R. S., Daly, J. W., Aracava, Y., and Albuquerque, E. X.** Interactions of Bupivacaine with Ionic Channels of the Nicotinic Receptor: Electrophysiological and Biochemical Studies, 293
- See *Aracava, Daly, Brookes, and Albuquerque*, 304
- Iwata, Kumiko.** See *Nakajima*, 430

J

- Jaques, Sandford, Jr., Tobes, Michael C., Sisson, James C., Baker, James A., and Wieland, Donald M.** Comparison of the Sodium Dependency of Uptake of *meta*-Iodobenzylguanidine and Norepinephrine into Cultured Bovine Adrenomedullary Cells, 539
- Javitch, Jonathan A., Blaustein, Robert O., and Snyder, Solomon H.** [³H]Mazindol Binding Associated with Neuronal Dopamine and Norepinephrine Uptake Sites, 35
- Jenden, Donald J.** See *Ringdahl, Resul, Ehler, and Dahlbom*, 170
- Johnson, David A.** See *Bolger, Dionne, Chrivia, and Taylor*, 57
- Johnson, Nicole, and Pasternak, Gavril W.** Binding of [³H]Naloxonazine to Rat Brain Membranes, 477
- Jordan, V. Craig**
- Lieberman, Mara E.** Estrogen-Stimulated Prolactin Synthesis *in Vitro*. Classification of Agonist, Partial Agonist, and Antagonist Actions Based on Structure, 279
- Lieberman, Mara E., Cormier, Ethel, Koch, Rick, Bagley, Jerome R., and Ruenitz, Peter C.** Structural Requirements for the Pharmacological Activity of Nonsteroidal Antiestrogens *in Vitro*, 272

K

- Kadlubar, F. F.** See *Mulder, Mays, and Hinson*, 342
- Kageyama, Hiroyasu.** See *Quach, Tang, Mocchetti, Guidotti, Meek, Costa, and Schwartz*, 255
- Kauffman, Frederick C.** See *Belinsky and Thurman*, 574
- Kelusky, Eric C., and Smith, Ian C. P.** The Influence of Local Anesthetics on Molecular Organization in Phosphatidylethanolamine Membranes, 314
- Knode, Marian C.** See *Glazer*, 381
- Koch, Rick.** See *Jordan, Lieberman, Cormier, Bagley, and Ruenitz*, 272
- Konno, Kenji.** See *Yokota, Shigeta, and De Clercq*, 376
- Korach, K. S.** See *Duax, Swenson, Strong, McLachlan, and Metzler*, 520
- Krieter, Philip A., Ziegler, D. M., Hill, Kristina E., and Burk, Raymond E.** Increased Biliary GSSG Efflux from Rat Livers Perfused with Thiocarbamide Substrates for the Flavin-Containing Monooxygenase, 122
- Kufe, Donald W., Munroe, D., Herrick, D., Egan, E., and Spriggs, D.** Effects of 1- β -D-Arabinofuranosylcytosine Incorporation on Eukaryotic DNA Template Function, 128
- See *Herrick*, 135

L

- Lazdunski, Michel.** See *Frelin, Vigne, and Schweitz*, 70
- Leeb-Lundberg, L. M. Fredrik.** See *Dickinson, Heald, Wikberg, DeBernardis, Caron, and Lefkowitz*, 187
- Lefkowitz, Robert J.** See *Dickinson, Leeb-Lundberg, Heald, Wikberg, DeBernardis, and Caron*, 187

- Lenschow, Volker.** See *Lohse and Schwabe*, 1
- Leslie, Barbara A.** See *Putney, McKinney, and Aub*, 261
- Li, Choh Hao.** See *Haynes and Smith*, 45
- Liarakos, Charles D.** See *Zytkovicz*, 369
- Lieberman, Mara E.** See *Jordan*, 279
- See *Jordan, Cormier, Koch, Bagley, and Ruenitz*, 272
- Liepe, Barbara.** See *McGee*, 51
- Linden, Joel.** Purification and Characterization of (-)-[¹²⁵I] Hydroxyphenylisopropyladenosine, an Adenosine R-Site Agonist Radioligand and Theoretical Analysis of Mixed Stereoisomer Radioligand Binding, 414
- Lo, Mathew, M. S.** See *Trifiletti and Snyder*, 228
- Loew, Gilda H., Nienow, John R., and Poulsen, Michael.** Theoretical Structure-Activity Studies of Benzodiazepine Analogues: Requirements for Receptor Affinity and Activity, 19
- Lohse, Martin J., Lenschow, Volker, and Schwabe, Ulrich.** Two Affinity States of R₁ Adenosine Receptors in Brain Membranes: Analysis of Guanine Nucleotide and Temperature Effects on Radioligand Binding, 1
- Lopez, Carlos.** See *Chou, Colacino, Feinberg, Watanabe, Fox, and Philips*, 587
- Lu, Lee-Jane Wang, and Randerath, Kurt.** Long Term Instability and Molecular Mechanism of 5-Azacytidine-Induced DNA Hypomethylation in Normal and Neoplastic Tissues *in Vivo*, 594
- Lukens, Carl B.** See *Woods and Eaton*, 336
- Luthin, Gary R., and Wolfe, Barry B.** [³H]Pirenzepine and [³H] Quinuclidinyl Benzilate Binding to Brain Muscarinic Cholinergic Receptors. Differences in Measured Receptor Density Are Not Explained by Differences in Receptor Isomerization, 164
- M**
- Maller, James L.** See *Sadler and Cooper*, 526
- Markstein, R.** See *Seiler*, 452
- Marletta, Michael A.** See *Collins*, 353
- Marnett, Lawrence J., Siedlik, Paul H., Ochs, Rudy C., Pagels, William R., Das, Mukul, Honn, Kenneth V., Warnock, Robert H., Tainer, Beth E., and Eling, Thomas E.** Mechanism of the Stimulation of Prostaglandin H Synthase and Prostacyclin Synthase by the Antithrombotic and Antimetastatic Agent, Nafazatrom, 328
- Marsh, Catherine L.** See *Hancock*, 439
- Martin-Caburi, J.** See *Garel, Domengot, Galacteros, and Beuzard*, 559
- Masters, Susan Brown, Harden, T. Kendall, and Brown, Joan Heller.** Relationships between Phosphoinositide and Calcium Responses to Muscarinic Agonists in Astrocytoma Cells, 149
- Mays, F. F.** See *Mulder, Kadlubar, and Hinson*, 342
- McGee, Richard, Jr., and Liepe, Barbara.** Acute Elevation of Cyclic AMP Does Not Alter the Ion-Conducting Properties of the Neuronal Nicotinic Acetylcholine Receptor of PC12 Cells, 51
- McKinney, Jerry S.** See *Putney, Aub, and Leslie*, 261
- McKinney, Michael, Stenstrom, Scott, and Richelson, Elliott.** Muscarinic Responses and Binding in a Murine Neuroblastoma Clone (N1E-115): Selective Loss with Subculturing of the Low-Affinity Agonist Site Mediating Cyclic GMP Formation, 156
- McLachlan, J.** See *Duax, Swenson, Strong, Korach, and Metzler*, 520
- McNicoll, Normand.** See *De Léan, Ong, Gutkowska, and Schiller*, 498
- Meek, James L.** See *Quach, Tang, Kageyama, Mocchetti, Guidotti, Costa, and Schwartz*, 255
- Metzler, M.** See *Duax, Swenson, Strong, Korach, and McLachlan*, 520
- Mitchell, Jerry R.** See *Smith and Hughes*, 112
- Mocchetti, Italo.** See *Quach, Tang, Kageyama, Guidotti, Meek, Costa, and Schwartz*, 255
- Moloney, Stephen J.** See *Spearman and Prough*, 566
- Mossoba, Magdi M.** See *Gutierrez, Fox, and Bachur*, 582
- Mulder, G. J., Kadlubar, F. F., Mays, J. B., and Hinson, J. A.** Reaction of Mutagenic Phenacetin Metabolites with Glutathione and DNA: Possible Implications for Toxicity, 342
- Munroe, D.** See *Kufe, Herrick, Egan, and Spriggs*, 128
- Murphy, S. D.** See *Sultatos, Basker, and Shao*, 99
- N**
- Nakajima, Tohru, and Iwata, Kumiko.** [³H]Ro 22-1319 (Piquindone) Binds to the D₂ Dopaminergic Receptor Subtype in a Sodium-Dependent Manner, 430
- Nebert, Daniel W.** See *Gonzalez and Tukey*, 117
- Nienow, John R.** See *Loew and Poulsen*, 19
- North, R. A.** See *Williams*, 489
- O**
- Ochs, Rudy C.** See *Marnett, Siedlik, Pagels, Das, Honn, Warnock, Tainer, and Eling*, 328
- Ong, Huy.** See *De Léan, Gutkowska, Schiller, and McNicoll*, 498
- P**
- Pace, Caroline S.** Influence of a Tumor-Promoting Phorbol Ester on the Electrical Response of B-cells to Glucose and Glyburide, 267
- Pagels, William R.** See *Marnett, Siedlik, Ochs, Das, Honn, Warnock, Tainer, and Eling*, 328
- Pasternak, Gavril W.** See *Johnson*, 477
- Perkins, John P.** See *Waldo, Doss, and Harden*, 424
- Perlman, Barry J.**
- Goldstein, Dora B. Membrane-Disordering Potency and Anticonvulsant Action of Valproic Acid and Other Short-Chain Fatty Acids, 83
- Goldstein, Dora B. Genetic Influences on the Central Nervous System Depressant and Membrane-Disordering Actions of Ethanol and Sodium Valproate, 547
- Philips, Frederick S.** See *Chou, Lopez, Colacino, Feinberg, Watanabe, and Fox*, 587
- Poulsen, Michael.** See *Loew and Nienow*, 19
- Prough, Russell A.** See *Spearman and Moloney*, 566
- Putney, James W., Jr., McKinney, Jerry S., Aub, Debra L., and Leslie, Barbara A.** Phorbol Ester-Induced Protein Secretion in Rat Parotid Gland: Relationship to the Role of Inositol Lipid Breakdown and Protein Kinase C Activation in Stimulus-Secretion Coupling, 261
- Q**
- Quach, Tam Thanh, Tang, Fai, Kageyama, Hiroyasu, Mocchetti, Italo, Guidotti, Alessandro, Meek, James L., Costa, Erminio, and Schwartz, Joan P.** Enkephalin Biosynthesis in Adrenal Medulla: Modulation of Proenkephalin mRNA Content of Cultured Chromaffin Cells by 8-Bromo-Adenosine 3',5'-Monophosphate, 255
- R**
- Rajerison, Rabary.** See *Guillon and Butlen*, 241
- Randerath, Kurt.** See *Lu*, 594
- Resul, Bahram.** See *Ringdahl, Ehlert, Jenden, and Dahlbom*, 170
- Riant, Pascale.** See *Urien, Albengres, Brioude, and Tillement*, 322
- Richelson, Elliott.** See *McKinney and Stenstrom*, 156
- Ringdahl, Björn, Resul, Bahram, Ehlert, Frederick J., Jenden, Donald J., and Dahlbom, Richard.** The Conversion of 2-Chloroalkylamine Analogues of Oxotremorine to Aziridinium Ions and Their Interactions with Muscarinic Receptors in the Guinea Pig Ileum, 170
- Rucci, George.** See *Gasiewicz*, 90
- Ruenitz, Peter C.** See *Jordan, Lieberman, Cormier, Koch, and Bagley*, 272
- S**
- Sadler, Susan E., Maller, James L., and Cooper, Dermot M. F.** Progesterone Inhibition of *Xenopus* Oocyte Adenylate Cyclase Is Not Mediated via the *Bordetella pertussis* Toxin Substrate, 526
- Schanche, Jon-Sverre, Schanche, Tone, Ueland, Per Magne, Holý, Antonin, and Votruba, Ivan.** The Effect of Aliphatic Ad-

- enine Analogues on S-Adenosylhomocysteine and S-Adenosylhomocysteine Hydrolase in Intact Rat Hepatocytes, 553
- Schanche, Tone.** See *Schanche, Ueland, Holý, and Votruba*, 553
- Schiller, Peter W.** See *De Léan, Ong, Gutkowska, and McNicoll*, 498
- Schwabe, Ulrich.** See *Lohse and Lenschow*, 1
- Schwartz, Alan.** See *Simmons*, 509
- Schwartz, Joan P.** See *Quach, Tang, Kageyama, Mocchetti, Guidotti, Meek, Costa, and Schwartz*, 255
- Schweitz, Hugues.** See *Frelin, Vigne, and Lazdunski*, 70
- Sebben-Perez, Michèle.** See *Bockaert and Cantau*, 180
- Seiler, M. P., and Markstein, R.** Further Characterization of Structural Requirements for Agonists at the Striatal Dopamine D₂ Receptor and a Comparison with Those at the Striatal Dopamine D₁ Receptor: Studies with a Series of Monohydroxyaminotetralins on Acetylcholine Release from Rat Striatum, 452
- Shao, M.** See *Sultatos, Basker, and Murphy*, 99
- Shigeta, Shiro.** See *Yokota, Konno, and De Clercq*, 376
- Siedlik, Paul H.** See *Marnett, Ochs, Pagels, Das, Honn, Warnock, Tainer, and Eling*, 328
- Sills, Matthew A., Wolfe, Barry B., and Frazer, Alan.** Multiple States of the 5-Hydroxytryptamine₁ Receptor as Indicated by the Effects of GTP on [3H]5-Hydroxytryptamine Binding in Rat Frontal Cortex, 10
- Simmons, Charles F., Jr., and Schwartz, Alan L.** Cellular Pathways of Galactose-Terminal Ligand Movement in a Cloned Human Hepatoma Cell Line, 509
- Sisson, James C.** See *Jaques, Tobes, Baker, and Wieland*, 539
- Smart, Robert C., and Zannoni, Vincent G.** DT-Diaphorase and Peroxidase Influence the Covalent Binding of the Metabolites of Phenol, the Major Metabolite of Benzene, 105
- Smith, Charles V., Hughes, Helen, and Mitchell, Jerry R.** Free Radicals *in Vivo*: Covalent Binding to Lipids, 112
- Smith, Ian C. P.** See *Kelusky*, 314
- Smith, Margaret E.** See *Haynes and Li*, 45
- Smith, McHardy M.** See *Evans, Tanner, and Harden*, 395
- Snowman, Adele M.** See *Trifiletti and Snyder*, 470
- Snyder, Solomon H.** See *Javitch and Blaustein*, 35
See *Trifiletti*, 458
See *Trifiletti and Lo*, 228
See *Trifiletti and Snowman*, 470
- Spearman, Marshall E., Moloney, Stephen J., and Prough, Russell A.** Effect of Cytosolic Components on the Metabolism of the Hydrazide Iproniazid, 566
- Spriggs, D.** See *Kufe, Munroe, Herrick, and Egan*, 128
- Stenstrom, Scott.** See *McKinney and Richelson*, 156
- Strong, P. D.** See *Duax, Swenson, Korach, McLachlan, and Metzler*, 520
- Sultatos, L. G., Basker, K. M., Shao, M., and Murphy, S. D.** The Interaction of the Phosphorothioate Insecticides Chlorpyrifos and Parathion and Their Oxygen Analogues with Bovine Serum Albumin, 99
- Swann, Allan.** See *Cantoni, Christie, Drath, and Costa*, 360
- Swenson, D. C.** See *Duax, Strong, Korach, McLachlan, and Metzler*, 520
- Suzuki, Yasuhiro.** See *Chao, Zysk, and Cheung*, 75
- T**
- Tainer, Beth E.** See *Marnett, Siedlik, Ochs, Pagels, Das, Honn, Warnock, and Eling*, 328
- Tang, Fai.** See *Quach, Kageyama, Mocchetti, Guidotti, Meek, Costa, and Schwartz*, 255
- Tank, A. William.** See *Yanagihara and Weiner*, 141
- Tanner, Laura I.** See *Evans, Smith, and Harden*, 395
- Taylor, Ian W.** See *Fox and Tripp*, 388
- Taylor, Palmer.** See *Ambler and Brown*, 405
See *Bolger, Dionne, Chrivia, and Johnson*, 57
- Thurman, Ronald G.** See *Belinsky and Kauffman*, 574
- Tillement, Jean-Paul.** See *Urien, Riant, Albengres, and Brioude*, 322
- Tobes, Michael C.** See *Jaques, Sisson, Baker, and Wieland*, 539
- Torrens, Y.** See *Beaujouan, Viger, and Glowinski*, 248
- Trifiletti, Rosario R.**
Lo, Mathew M. S., Snyder, Solomon H. Kinetic Differences between Type I and Type II Benzodiazepine Receptors, 228
- Snowman, Adele M., and Snyder, Solomon H.** Anxiolytic Cyclopyrrolone Drugs Allosterically Modulate the Binding of [³⁵S]t-Butylbicyclophosphorothionate to the Benzodiazepine/γ-Aminobutyric Acid-A Receptor/Chloride Anionophore Complex, 470
- Snyder, Solomon H.** Anxiolytic Cyclopyrrolones Zopiclone and Suriclone Bind to a Novel Site Linked Allosterically to Benzodiazepine Receptors, 458
- Tripp, Edith H.** See *Fox and Taylor*, 388
- Tukey, Robert H.** See *Gonzalez and Nebert*, 117
- U**
- Ueland, Per Magne.** See *Schanche, Schanche, Holý, and Votruba*, 553
- Urien, Saik, Riant, Pascale, Albengres, Edith, Brioude, Robert, and Tillement, Jean-Paul.** *In Vitro* Studies on the Distribution of Probuco among Human Plasma Lipoproteins, 322
- V**
- Venter, J. Craig, Horne, Peter, Eddy, Barbara, Greguski, Roger, and Fraser, Claire M.** Alpha₁-Adrenergic Receptor Structure, 196
- Viger, A.** See *Beaujouan, Torrens, and Glowinski*, 248
- Vigne, Paul.** See *Frelin, Schweitz, and Lazdunski*, 70
- Votruba, Ivan.** See *Schanche, Schanche, Ueland, and Holý*, 553
- W**
- Waldo, Gary L., Doss, Robert C., Perkins, John P., and Harden, T. Kendall.** Use of a Density Shift Method to Assess Beta-Adrenergic Receptor Synthesis during Recovery from Catecholamine-Induced Down-Regulation in Human Astrocytoma Cells, 424
- Warnock, Robert H.** See *Marnett, Siedlik, Ochs, Pagels, Das, Honn, Tainer, and Eling*, 328
- Watanabe, Kyoichi A.** See *Chou, Lopez, Colacino, Feinberg, Fox, and Philips*, 587
- Weiner, Norman.** See *Yanagihara and Weiner*, 141
- Wieland, Donald M.** See *Jaques, Tobes, Sisson, and Baker*, 539
- Wikberg, Jarl E. S.** See *Dickinson, Leeb-Lundberg, Heald, De-Bernardis, Caron, and Lefkowitz*, 187
- Williams, J. T., and North, R. A.** Opiate-Receptor Interactions on Single Locus Coeruleus Neurons, 489
- Wolberg, Gerald, and Zimmerman, Thomas P.** Effects of Calmodulin Antagonists on Immune Mouse Lymphocytes, 286
- Wolfe, Barry B.** See *Luthin*, 164
See *Sills and Frazer*, 10
- Woods, James S., Eaton, David L., and Lukens, Carl B.** Studies on Porphyrin Metabolism in the Kidney: Effects of Trace Metals and Glutathione on Renal Uroporphyrinogen Decarboxylase, 336
- Wreggett, Keith A., and DeLéan, André.** The Ternary Complex Model: Its Properties and Application to Ligand Interactions with the D₂-Dopamine Receptor of the Anterior Pituitary Gland, 214
- Y**
- Yanagihara, Nobuyuki, Tank, A. William, and Weiner, Norman.** Relationship between Activation and Phosphorylation of Tyrosine Hydroxylase by 56 mM K⁺ in PC12 Cells in Culture, 141
- Yokota, Tomoyuki, Konno, Kenji, Shigeta, Shiro, and De Clercq, Erik.** Comparative Inhibition of DNA Polymerases from Varicella Zoster Virus (TK⁺ and TK⁻) Strains by (E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-Triphosphate, 376
- Z**
- Zannoni, Vincent G.** See *Smart*, 105

- Zaremba, Terrye G., and Fishman, Peter H.** Desensitization of Catecholamine-Stimulated Adenylate Cyclase and Down-Regulation of *Beta*-Adrenergic Receptors in Rat Glioma C6 Cells: Role of Cyclic AMP and Protein Synthesis, 206
- Ziegler, D. M.** See *Krieter, Hill, and Burk*, 122
- Zimmerman, Thomas P.** See *Wolberg*, 286
- Zysk, John R.** See *Chao, Suzuki, and Cheung*, 75
- Zytkovicz, Thomas H., and Liarakos, Charles D.** Factors Influencing the Covalent Binding of (\pm)-7 β ,8 α -Dihydroxy-9 α ,10 α -epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene to Ribonucleic Acids, 369

CUMULATIVE SUBJECT INDEX FOR VOLUMES 25 AND 26

A

- A23187
effect on [³H]inositol metabolism in GH₃ pituitary tumor cells, **25**, 201
- Acetaminophen
benzoquinone reduction, **25**, 151
covalent binding, **26**, 112
- Acetylcholine
-activated ionic channels, **26**, 304
inhibitors, **26**, 57
noise analysis, **25**, 384
receptor
-ionic channel complex, **25**, 384, 395, **26**, 293
nicotinic, **25**, 384, **26**, 51
phencyclidine binding (ray), **25**, 360
sensitivity, junctional and extrajunctional regions, **25**, 395
- Acetylcholinesterase
A₁₂, beta-endorphin inhibition, **26**, 45
molecular forms, **26**, 45
- Action potential
anticonvulsants, **25**, 228
inhibition by verapamil (crayfish), **25**, 369
local anesthetics, **25**, 219
- Activation, dCMP deaminase, by 5-aza-dCTP, **25**, 436
- Activity
antineoplastic, 3'-amino-3'-deoxythymidine, **25**, 441
biological, 16 α , 17 α -acetal-substituted glucocorticoids, **25**, 70
- Adenosine dialdehyde
S-adenosylhomocysteine hydrolase and transmethylation, L929 cells (mouse), **25**, 418
inhibition (mouse), **25**, 418
- Adenosine receptors, brain, **26**, 1
- S-Adenosylhomocysteine
effect of aliphatic adenine analogues (rat), **26**, 553
hydrolase, L929 cells, effects of adenosine dialdehyde (mouse), **25**, 418
- S-Adenosylmethionine-dependent transmethylation, adenosine dialdehyde (mouse), **25**, 418
- Adenylate cyclase
 γ -aminobutyric acid (rat), **25**, 24
cannabinoid inhibition, **26**, 532
desensitization and down-regulation, glioma cells (rat), **26**, 206
dopamine-sensitive (carp, rat), **25**, 18
inhibitory (rat), **25**, 24
oocyte, progesterone inhibition, **26**, 526
stimulation, **26**, 180
- Adrenal
chromaffin cells
effect of bungarotoxin polypeptide, **25**, 327
nicotinic receptor function, **25**, 327
cortical cells
polycyclic aromatic hydrocarbon metabolism (bovine), **25**, 476
primary culture (bovine), **25**, 476
medulla
enkephalin, **26**, 255
opiate receptors (bovine), **25**, 38
- Adrenergic receptor
*alpha*₁
agonists in vas deferens (rat), **25**, 56
probe, high affinity, high specific activity, **26**, 187
receptor structure, **26**, 196
- beta*
desensitization and down-regulation, **26**, 206
on intact S49 lymphoma cells, **25**, 209
stimulation, phosphatidylinositol turnover (hamster), **25**, 64
- Adrenocorticotropin, suppression of benz[a]pyrene metabolism (bovine), **25**, 476
- Affinity labeling, **26**, 187
- Agonist
*alpha*₁-adrenergic receptors in vas deferens (rat), **25**, 56
affinity
 β -adrenergic receptors, on intact S49 lymphoma cells, **25**, 209
states in brain (calf), **25**, 10
effect on *beta*-adrenergic receptors in S49 lymphoma cells, **25**, 209
muscarinic, **26**, 149
nicotinic acetylcholine receptor-ionic channel complex, pyridostigmine action, **25**, 92
- Ah locus in mice, **26**, 117
- Albumin
binding
anti-inflammatory drugs, **25**, 137
nonsteroidal, **25**, 137
co-binding of two drugs, **25**, 137
- Alcohol
allyl, metabolism in liver (rat), **25**, 158
inhibition of *delta* subclass of opioid binding sites, **25**, 249
- Aldose reductase
inhibition (human), **25**, 425
placenta (human), **25**, 425
- Alkylation, site-directed, opioid receptors, **25**, 337, 343
- Allyl alcohol metabolism, in liver (rat), **25**, 158
- Allylisopropylacetamide
cytochrome P-450 destruction (rat), **25**, 310
prosthetic heme adducts (rat), **25**, 310
- Alrestatin, inhibition of placenta aldose reductase (human), **25**, 425
- Amiloride
effect on skeletal muscle (chick), **25**, 131
structure-activity relationships, **25**, 131
- Amine, tertiary muscarinic receptor binding, **25**, 46
- Amino acid analysis, hepatic isozyme (rabbit), **25**, 494
- Aminotetralins, dopamine D₂ receptor characterization (rat), **26**, 452
- γ -Aminobutyric acid
binding
in brain (rat), **25**, 352
modulation by calcium (rat), **25**, 352
receptors, inhibitory cyclase (rat), **25**, 24
- γ -Aminobutyric acid A
recognition sites, γ -aminobutyric acid binding to (rat), **25**, 352
- γ -Aminobutyric acid B
receptors, in brain (rat), **25**, 24
recognition sites, γ -aminobutyric acid binding to (rat), **25**, 352
- 3'-Amino-3'-deoxythymidine, antineoplastic activity, **25**, 441
- 3'-Aminothymidine
diphosphate, metabolites, **25**, 441
inhibitor, **25**, 441
mechanism of action, **25**, 441
monophosphate, metabolites, **25**, 441
triphosphate
DNA polymerase inhibition, **25**, 441
metabolites, **25**, 441
- Ammonium, quaternary analogues of tertiary amines, muscarinic receptor binding, **25**, 46

- Analogue
 aliloride, structure-activity relationships, **25**, 131
 dimethylated, *N*-acetyl-*p*-benzoquinone imine, **25**, 151
 thymidine
 antineoplastic activity, **25**, 441
 phosphorylation, **25**, 446
- Anesthesia, theory, **25**, 123
- Anesthetic
 inhalation, membrane expansion and, **25**, 123
 local
 bupivacaine, **26**, 293
 effect on sodium channels, **25**, 219
 open channel blockade, **26**, 304
 membrane action, **26**, 314
- Angiotensin
 -converting enzyme
 pulmonary (rabbit), **25**, 287
 substance P as substrate, hydrolysis, (rabbit), **25**, 287
 -induced receptor-effector coupling (bovine), **26**, 498
- Antagonism, feedback inhibition, **25**, 446
- Antagonist
 calcium channel
 binding sites, **25**, 235
 sensitivity of phencyclidine (crayfish), **25**, 369
 calcium, in secretion (rat), **25**, 51
N-methyl phenomenon (carp, rat), **25**, 18
 thymidine kinase, **25**, 446
- Antibiotic
 avoparcin, nuclear magnetic resonance studies, **25**, 275
 glycopeptide
 nuclear magnetic resonance studies, **25**, 275
 nuclear magnetic resonance study, **25**, 281
- Anticonvulsant
 carbamazepine, **25**, 228
 diphenylhydantoin, **25**, 228
 valproic acid, other short-chain fatty acids, **26**, 83
- Antiestrogens, nonsteroidal, structural requirements for pharmacological activity, **26**, 272
- Aphidicolin, **26**, 128
- Apomorphine, enantiomers, interactions with dopamine receptors (carp, rat), **25**, 18
- 1- β -D-Arabinofuranosylcytosine
 effects on DNA during UV repair, **25**, 322
 incorporation into DNA, **25**, 322
- 1- β -D-Arabinosyl-5-azacytosine effects on DNA, human colon cancer, **26**, 381
- ARA-C incorporation, into DNA, **26**, 128
- Ascorbate, covalent binding, **26**, 105
- ATP, energy metabolism, **26**, 286
- Avoparcin
 conformation, nuclear magnetic resonance study, **25**, 275, 281
 -peptide complexes, structure, **25**, 275
 receptor, bacterial cell wall, **25**, 281
- 5-Azacytidine
 -induced unstable DNA hypomethylation, **26**, 594
 synthesis and methylation of DNA, human colon carcinoma, **26**, 381
- 5-Azadeoxycytidine-5'-monophosphate, substrate for dCMP deaminase, **25**, 436
- 5-Azadeoxycytidine-5'-triphosphate, activator for dCMP deaminase, **25**, 436
- 5-Azadeoxycytidine, nucleotides, kinetic studies with dCMP deaminase, **25**, 436
- B**
- Bacteria, cell wall, avoparcin receptor, **25**, 281
- Batrachotoxinin A 20- α -benzoate, 3 H-labeled, inhibition of binding, **25**, 219
- BE 2254, 125 I-labeled, binding in vas deferens (rat), **25**, 56
- Benzene
 metabolites, **26**, 105
 toxicity, **26**, 105
- Benzodiazepine
 binding
 sites, peripheral, **25**, 349
 structural requirements, **25**, 349
 1,4-Benzodiazepines, conformational and electronic properties, **26**, 19
 Benzomorphan sites, binding characteristics, **26**, 484
- Benzo[a]pyrene
 dilepoxide, **26**, 369
 saturable, high affinity site(s), **26**, 353
- Berenil, nonintercalative binding, **25**, 452
- Binding
 albumin, nonsteroidal, **25**, 137
 γ -aminobutyric acid modulation by calcium (rat), **25**, 352
 anti-inflammatory drugs, by albumin, **25**, 137
 benzodiazepine
 peripheral sites, **25**, 349
 structural requirements, **25**, 349
 bisantrene, to DNA, **25**, 178
 calcium channel antagonist, tissue heterogeneity, **25**, 235
 competitive, α -bungarotoxin, **25**, 395
 constants, stoichiometric, **25**, 137
 diarylamidines, nonintercalative, **25**, 452
 dihydrotetrabenazine, comparison with reserpine binding (bovine), **25**, 113
 DNA, by HgCl₂, **26**, 360
 inhibition, [3 H]batrachotoxin in A 20- α -benzoate, **25**, 219
 mitoxantrone, to DNA, **25**, 178
 muscarinic receptor, tertiary amines, **25**, 46
 nicotinic acetylcholine receptor-ionic channel complex, pyridostigmine action, **25**, 92
 [3 H]nitrendipine, heterogeneity of sites, **25**, 235
 noncompetitive, gephyrotoxin interaction, **25**, 395
 nonintercalative
 berenil, **25**, 452
 diarylamidines, **25**, 452
 stilbamidine, **25**, 452
 opioid
 brain (guinea pig), **25**, 337
 discrimination of sites in brain (rat), **25**, 242
 selective inhibition of δ subclass, **25**, 249
 μ ₁ sites, **25**, 29
 3 H-opioid, high-affinity, biochemical characterization, **25**, 29
 pBR322, plasma, by drugs, **25**, 178
 perhydrohistrionicotoxin, inhibition, **25**, 395
 phencyclidine
 inhibition by Ca²⁺ antagonists (crayfish), **25**, 369
 to acetylcholine receptor (ray), **25**, 360
 plasma protein, **26**, 322
 PM2, circular DNA, by drugs, **25**, 178
 polynucleotide, in intestinal cytosol (chicken), **25**, 86
 radioligand
 in vas deferens (rat), **25**, 56
 prediction, **25**, 1
 thermodynamics, **26**, 1
 receptor, 16 α ,17 α -acetal-substituted glucocorticoids, **25**, 70
- Binding
 reserpine
 comparison with dihydrotetrabenazine binding (bovine), **25**, 113
 to chromaffin granule membranes (bovine), **25**, 113
 site, analysis, versus stoichiometric analysis, **25**, 137
 stoichiometry, **25**, 137
 structure-activity relations with tamoxifen series, **26**, 272
 Torpedo electrolax, **26**, 293
- Biochemistry, high-affinity 3 H-opioid binding, **25**, 29

Bioassay

opioid receptors in brain (guinea pig), **25**, 343

Biosynthesis, purine, glycinamide transformylase, **25**, 294

Bisantrene

antitumor activity, **25**, 178

binding to DNA, **25**, 178

Bordetella pertussis, toxin substrate, and progesterone inhibition, **26**, 526

Brain

γ -aminobutyric acid binding (rat), **25**, 352

cholesterol, ethanol effects (mouse), **25**, 401

D₂-dopamine receptors (calf), **25**, 10

gangliosides

ethanol effects (mouse), **25**, 401

membrane effects, **25**, 410

Brain

membrane

effect of ethanol and pentobarbital, **25**, 410

lipid composition, physical properties (mouse), **25**, 401

new type of tachykinin-binding site (rat), **26**, 248

phospholipids, ethanol effects (mouse), **25**, 401

Bromobenzene, **26**, 112

(E)-5-(2-Bromovinyl)-2'-deoxyuridine 5'-triphosphate, effect on varicella zoster virus, **26**, 376

 α -Bungarotoxin

competitive binding, **25**, 395

polypeptide

adrenal chromaffin cells, **25**, 327

purification and characterization, **25**, 327

Bupivacaine

noncompetitive antagonists, **26**, 293, 304

displacement by histrionicotoxin, **26**, 293

[³⁵S]-t-Butylbicyclophosphorothionate

binding modulation by cyclopyrrolone drugs, **26**, 470

C

Ca²⁺, *see also* Calcium

α ₁-adrenergic receptors and phosphatidylinositol, **26**, 405

channel (crayfish), **25**, 369

conductance, **26**, 267

dependency, [³H]norepinephrine release (rat), **25**, 379

-dependent phosphodiesterase, **26**, 75

respiration in brown fat cells (hamster), **25**, 64

Calcium, *see also* Ca²⁺

channel

antagonists, **25**, 235

in secretion (rat), **25**, 51

sensitivity of phencyclidine (crayfish), **25**, 369

efflux, **26**, 149

interaction with protein kinase C, **26**, 261

mobilization, **26**, 149

modulation of γ -aminobutyric acid binding (rat), **25**, 352

receptor regulation (rat), **25**, 51

role as second messenger (rat), **25**, 51

Calmodulin

activation by metals, **26**, 75

antagonists, **26**, 286

effect on γ -aminobutyric acid binding in brain (rat), **25**, 352

Cannabinoid drugs, inhibition of adenylate cyclase, **26**, 532

Captopril, potentiation, substance P activity *in vivo* (rabbit), **25**, 287

Carbachol, phosphorylation of myosin light chain and phosphorylase (dog), **25**, 267

Carbamazepine, effect on sodium channels, neuroblastoma cells and synaptosomes, **25**, 228

Carbamylcholine, effect on thyroid (dog), **25**, 261

Carbon tetrachloride

metabolism

oxygen dependency (rat), **25**, 318

to phosgene (rat), **25**, 318

reductive oxygenation (rat), **25**, 318

Carboxyl-terminal, tripeptidyl hydrolysis of substance P, **25**, 287

Carboxymethylation, protein (mouse), **25**, 418

N-(1-(S)-Carboxy-3-phenylpropyl)-L-alanyl-L-proline, potentiation of substance P activity (rabbit), **25**, 287

Catecholamine

α ₁ in brown fat cells (hamster), **25**, 64

carrier, in chromaffin granule membranes (bovine), **25**, 113

uptake, chromaffin granule membranes (bovine), **25**, 113

Caudate nucleus, D₂-dopamine receptors (calf), **25**, 10

Cell

adrenal chromaffin

nicotinic receptor function, **25**, 327

primary culture, **25**, 327

Cell

adrenal cortical

metabolism of polycyclic aromatic hydrocarbon (bovine), **25**, 476

primary culture (bovine), **25**, 476

bacterial, avoparcin receptor of cell wall, **25**, 281

C6-2B, effect of forskolin on cyclic AMP accumulation and hormone responses (rat), **25**, 256

fat

metabolism (hamster), **25**, 64

phosphatidylinositol turnover (hamster), **25**, 64

respiration (hamster), **25**, 64

granule, cerebellar, γ -aminobutyric acid B receptors (rat), **25**, 24

HKSV28, inhibition of growth by 5,11-methenyltetrahydrohomofolate, **25**, 294

intact, receptors, **25**, 209

L929, S-adenosylmethionine-dependent transmethylation (mouse), **25**, 418

lethality, **25**, 322

leukemic, lethality of 5-methyl-2'-deoxycytidine (human), **25**, 431

S49 lymphoma, β -adrenergic receptors, **25**, 209

neuroblastoma, voltage-sensitive sodium channels, **25**, 228

pheochromocytoma, [³H]norepinephrine release (rat), **25**, 379

GH₃ pituitary tumor, effect of thyrotropin-releasing hormone, **25**, 193

thymidylate synthetase levels, effect of 5-fluorouracil, **25**, 171

Central nervous system depressants, ethanol and sodium valproate (mice), **26**, 547

Cerebellum

γ -aminobutyric acid B receptors (rat), **25**, 24

granule cells (rat), **25**, 24

Chain termination, relative, **26**, 128

Channel conductance, **26**, 304

Characterization, bungarotoxin polypeptide, **25**, 327

2-Chloroalkylamine oxotremorine derivative, **26**, 170

β -Chlornaltrexamine, selective protection, **25**, 337

Cholesterol, brain, ethanol effects (mouse), **25**, 401

Chromaffin

cell cultures, 8-Bromo-cyclic AMP treatment, **26**, 255

granule membranes, reserpine binding (bovine), **25**, 113

Chromatography, affinity, dye-ligands (chicken), **25**, 79

Conductance, Ca²⁺ and K⁺, **26**, 267

Conjugation, glutathione, N-acetyl-p-benzoquinone imine, **25**, 151

Conformation

avoparcin

nuclear magnetic resonance study, **25**, 275, 281

Cross-linking, photoaffinity, **26**, 187

Cyclic AMP

accumulation in thyroid, effects of alkylated xanthines (dog), **25**, 261

forskolin-stimulated, in C6-2B cells (rat), **25**, 256

metabolism, regulation by different molecular mechanisms, **26**, 395

neuronal nicotinic receptors, **26**, 51

receptor down-regulation, **26**, 206

- receptor modulation, 26, 156
- Cyclic GMP receptor stimulation, 26, 156
- Cyclopyrrolone
 - binding, benzodiazepine receptors, 26, 458
 - TBPS interactions, 26, 470
- Cytidine deaminase activity, malignant hematopoietic cells (human), 25, 431
- Cytochrome
 - P-450
 - allylisopropylacetamide destruction (rat), 25, 310
 - extrahepatic, 25, 185
 - inactivation (rat), 25, 310
 - isozymes, 25, 185
 - liver microsomal, isozymes 3a and 6 (rabbit), 25, 494
 - metabolism of carbon tetrachloride to phosgene (rat), 25, 318
 - microsomal, metabolism of carbon tetrachloride (rat), 25, 318
 - reductase, hemoglobin coupling, 25, 467
 - 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-inducible, 25, 185
- Culture
 - primary
 - adrenal chromaffin cells, 25, 327
 - adrenal cortical cells (bovine), 25, 476
- Cytolysis, lymphocyte-mediated, 26, 286
- Cytosol, intestinal, 1,25-dihydroxyvitamin D₃ complexes (chicken), 25, 86
- Cytotoxicity, thymidine analogues, 25, 446

D

- dCMP deaminase
 - activation by 5-aza-2'-deoxycytidine, 25, 436
 - inhibition by dTTP, 25, 436
- Density shift method, assessment of *beta*-adrenergic receptor synthesis, 26, 424
- Deoxyadenosine, lymphotoxicity of, 26, 388
- 2'-Deoxy-5-azacytidine, synthesis and methylation of DNA colon carcinoma (human), 26, 381
- Desensitization
 - extrajunctional, junctional, acetylcholine, 25, 395
 - neuromuscular synapse, 25, 92, 102
 - nicotinic acetylcholine receptor-ionic channel complex, pyridostigmine action, 25, 92
- Deuterium NMR and anesthetics, 26, 314
- Diacylglycerol, 26, 267
- 1,2-Diacylglycerol, accumulation in GH₃ pituitary tumor cells, 25, 193
- Diarylaminides, nonintercalative binding, 25, 452
- Diazepam, effect on γ -aminobutyric binding in brain (rat), 25, 352
- Diaziquone, electrochemical reduction, 26, 582
- Diethylstilbestrol, structure, binding, and activity, 26, 520
- Dihydrotrabenazine binding, comparison, reserpine binding (bovine), 25, 113
- 1,25-Dihydroxyvitamin D₃
 - receptor complexes
 - dye-ligand interactions (chicken), 25, 79, 86
 - in intestinal cytosol (chicken), 25, 86
- Dimethylation, *N*-acetyl-*p*-benzoquinone analogues, 25, 151
- Dimethylnitrosamine, 26, 112
- Diphenylhexatriene, 26, 83
- Diphenylhydantoin, effect on sodium channels in neuroblastoma cells and synaptosomes, 25, 228
- Diprenorphine, *in vivo* receptor binding (rat), 25, 242
- Dipyridamole, prostacyclin stimulation, 26, 328
- DNA
 - analytical flow cytometry, 26, 388
 - bisantrone binding, 25, 178
 - damage by HgCl₂, 26, 360
 - effects of 1- β -D-arabinofuranosylcytosine during UV repair, 25, 322
 - hypomethylation, unstable, 5-azacytidine-induced, 26, 594

- mitoxantrene binding, 25, 178
- polymerase
 - inhibition by 3'-aminothymidine triphosphate, 25, 441
 - viral, 26, 376
 - synthesis and methylation, human colon cancer, 26, 381
- Dopamine
 - receptor
 - D₂, in brain (calf), 25, 10
 - multiple (carp, rat), 25, 18
 - sensitive adenylate cyclase (carp, rat), 25, 18
 - uptake
 - inhibition of, 25, 35
 - sodium and chloride dependency, 26, 35
- Drug
 - antiepileptic, inhibitory action, 25, 228
 - anti-inflammatory, albumin binding, 25, 137
 - dependent glutathione oxidation, 26, 122
 - induced folate deficiency (mouse), 25, 459
 - metabolism, extrahepatic, 25, 185
- DT-diaphorase, detoxification, 26, 105
- dUMP, relationship to inhibition of thymidylate synthase by 5-fluorouracil, 25, 303
- Dye
 - ligand
 - affinity chromatography (chicken), 25, 79
 - interaction specificity, 25, 86
 - interactions with 1,25-dihydroxyvitamin D₃-receptor complexes (chicken), 25, 79
 - polyribonucleotide interaction (chicken), 25, 86
- Dynorphin, pharmacological selectivity, 25, 343

E

- Electrochemical gradient, H⁺ in chromaffin granule membranes (bovine), 25, 113
- Electrode, O₂, miniature, 25, 158
- Electron microscopy, evidence for drug-DNA binding, 25, 178
- Electrophorus* electric organ, 26, 45
- Electroplaque, acetylcholine receptor (rat), 25, 360
- Eledoisin, high-affinity binding, 26, 248
- Empirical energy calculations, 26, 19
- Enantiomer, apomorphine, interactions with dopamine receptors (carp, rat), 25, 18
- Endoreduplication, 26, 128
- β -Endorphin
 - analogues, 26, 45
 - pharmacological selectivity, 25, 343
 - species differences, 26, 45
- End-plate current
 - alteration by pyridostigmine, 25, 92
 - amplitude depression shortening, 25, 384
 - miniature, 26, 293
 - "rundown" induced by gephyrotoxin, 25, 384
 - biosynthesis in adrenal medulla, 26, 255
 - mu*₁ binding sites, 25, 29
 - pharmacological selectivity, 25, 343
 - synthesis, 8-Bromo-cyclic AMP stimulation, 26, 255
- Enzyme
 - pulmonary
 - angiotensin-converting (rabbit), 25, 287
 - substance P hydrolysis (rabbit), 25, 287
- Epilepsy, inhibitory action of anticonvulsants, 25, 228
- Erythrocyte sickling, inhibition, by thiol reagents, 26, 559
- Erythroleukemia cells, murine, 26, 135
- Estrogen-stimulated prolactin synthesis, 26, 279
- Ethanol
 - cell-membrane disordering potency, 26, 83
 - comparison, sodium valproate (mice), 26, 547

Ethanol—*Continued*

- effect on membrane fluidity, **25**, 410
 - induction of liver microsomal cytochrome P-450 isozyme 3a (rabbit), **25**, 494
 - membrane action, effect of gangliosides, **25**, 410
 - peptide mapping (rabbit), **25**, 494
 - tolerance, effect on physical properties and lipid composition, brain membranes (mouse), **25**, 401
- Etorphine, *in vivo* receptor binding (rat), **25**, 242

F

- Fat cell, metabolism, phosphatidylinositol turnover, and respiration (hamster), **25**, 64
- Fatty acids, anticonvulsant and sedative action, **26**, 83
- FdUMP, *see* 5-Fluorodeoxyuridine-5'-monophosphate
- Fibroblast, effect of amiloride (chick), **25**, 131
- Flavin-containing monooxygenase, **26**, 122
- Flavin monooxygenase, mechanistic studies of, **26**, 348
- Fluctuation analysis, shortening of channel lifetime, **26**, 293
- Fluidity
- membrane
 - effect of ethanol tolerance (mouse), **25**, 401
 - ethanol effects, **25**, 401
 - fluorescent probes (mouse), **25**, 401
- Fluorescence polarization, **26**, 83
- Fluorescent acylcholines, **26**, 57
- Fluorescent energy transfer, **26**, 57
- Fluorescent probe, membrane fluidity (mouse), **25**, 401
- 5-Fluoro-2'-deoxyuridine-5'-monophosphate binding to thymidylate synthetase, **25**, 171
- effect of 5-fluorouracil, **25**, 171
 - relationship to inhibition of thymidylate synthase by 5-fluorouracil, **25**, 303
- 2'-Fluoro-5-iodo-1- β -D-arabinofuranosylcytosine, metabolic effect, virus-infected cells, **26**, 587
- 5-Fluorouracil
- effect on cellular thymidylate synthetase levels, **25**, 171
 - incorporation into preribosomal RNA, **26**, 135
 - inhibition of thymidylate synthase, **25**, 303
- Folate
- biochemistry, effect of phenytoin (mouse), **25**, 459
 - deficiency, drug-induced (mouse), **25**, 459
 - distribution in liver (mouse), **25**, 459
- Forskolin
- potentiated hormone responses in C6-2B cells (rat), **25**, 256
 - stimulated cyclic AMP accumulation in C6-2B cells (rat), **25**, 256
- 2-Furamide, **26**, 112
- Furosemide, **26**, 112

G

- G_i block, **26**, 388
- Ganglioside
- brain
 - effect on membrane actions of ethanol and phenobarbital, **25**, 410
 - ethanol effects (mouse), **25**, 401
 - membrane effects, **25**, 410
- Gene activation, **26**, 117
- Genetics (mouse), **26**, 117
- Gephyrotoxin
- effect on neuromuscular transmission, **25**, 395
 - interaction
 - noncompetitive binding, **25**, 395
 - with acetylcholine receptor-ionic channel complex, **25**, 384
- Glucocorticoid
- 16 α ,17 α -acetal-substituted action, **25**, 70
 - potency *in vivo* and *in vitro*, **25**, 70

receptor

- ligand structural specificity requirements, **25**, 70
 - skeletal muscle (rat), **25**, 70
- Glucuronidation, 7-hydroxycoumarin in liver lobule (rat), **25**, 487
- Glucuronosyltransferase activity in liver lobule (rat), **25**, 487
- Glutathione
- conjugation, *N*-acetyl-*p*-benzoquinoneimine, **25**, 151
 - oxidation, drug-dependent, **26**, 122
 - reaction of mutagenic phenacetin metabolites, **26**, 342
- Glycinamide transformylase, *de novo* purine biosynthesis, **25**, 294
- Glycopeptide, antibiotics and nuclear magnetic resonance studies, **25**, 275, 281
- Glycoproteins, galactose-terminal, cellular pathways (human), **26**, 509
- Glycoproteins, galactose-terminal, cellular pathways (human), **26**, 509
- Granule cell, γ -aminobutyric acid B receptors (rat), **25**, 24
- Guanine
- nucleotides
 - effects on D₂-dopamine receptors in brain (calf), **25**, 10
 - receptor affinity changes, **26**, 1

H

- H⁺
- electrochemical gradient, chromaffin granule membranes (bovine), **25**, 113
 - /H⁺ exchange system, **25**, 131
- Heavy metal toxicity, **26**, 75
- Heme
- adducts, structure (rat), **25**, 310
 - prosthetic adducts, inactivated cytochrome P-450 (rat), **25**, 310
- Hemoglobin
- autooxidation, **25**, 467
 - catalytic activity, **25**, 467
 - cytochrome P-450-like activity, **25**, 467
 - monooxygenase activity, **25**, 467
 - substrate specificity, **25**, 467
- Hepatoma
- Hep G2, galactose-terminal ligand movement, **26**, 509
- Hepatotoxicity
- lobular, allyl alcohol (rat), **25**, 158
- Heterogeneity
- tissue, calcium channel antagonist binding sites, **25**, 235
- HKSV28 cell
- inhibition of growth by 5,11-methenyltetrahydrohomofolate, **25**, 294
- Hoechst 33342 fluorescence, bromodeoxyuridine quenching, **26**, 388
- Homofolic acid
- inhibition of *de novo* purine biosynthesis, **25**, 294
- Hormone
- action, models for, **26**, 214
 - forskolin-potentiated responses in C6-2B cells (rat), **25**, 256
 - gonadotropin-releasing actions (rat), **25**, 51
 - luteinizing, release (rat), **25**, 51
 - thyrotropin-releasing
 - effect on GH₃ pituitary tumor cells, **25**, 193
 - stimulated [³H]inositol metabolism in GH₃ pituitary tumor cells, **25**, 201
- Hybridization, RNA-DNA, **26**, 117
- Hydrocarbons
- polycyclic aromatic
 - competitive binding, **26**, 353
 - metabolism, adrenal cortical cells (bovine), **25**, 476
 - steroidogenesis, adrenal cortical cells (bovine), **25**, 476
- Hydrolysis
- tripeptidyl, substance P, **25**, 287
- Hydroperoxyflavin
- model for FMO, **26**, 348

7-Hydroxycoumarin
 glucuronidation in liver lobule (rat), **25**, 487

N-Hydroxy-*p*-phenetidine
 carcinogenic activity, **26**, 342

(-)[¹²⁵I]Hydroxyphenylisopropyladenosine
 purification, characterization, and radioligand binding, **26**, 414

³H-5-Hydroxytryptamine
 binding, and effects of GTP, **26**, 10

I

ICRF-159, cell cycle analysis, **26**, 388

Ileum, opioid receptors (guinea pig), **25**, 343

Imidazole, induction of liver microsomal cytochrome P-450 isozymes
 3a and 6 (rabbit), **25**, 494

Inhalation anesthetics, and membrane expansion, **25**, 123

Inhibition
 action potential, verapamil (crayfish), **25**, 369
 adenosine dialdehyde (mouse), **25**, 418
 aldose reductase, by alrestatin (human), **25**, 425
 binding, [³H]batrachotoxinin A 20- α -benzoate, **25**, 219
 dCMP deaminase, by dTTP, **25**, 436
 DNA polymerase, by 3'-aminothymidine triphosphate, **25**, 441
 feedback, dThd kinase activity, **25**, 446
 HKSV28 cell growth, by 5,11-methenyltetrahydrohomofolate, **25**, 294
 selective, *delta* subclass of opioid binding sites, **25**, 249
 thymidylate synthase, by 5-fluorouracil, **25**, 303
 voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes, **25**, 228

Inhibitory potency, amino acid sequence requirements, **26**, 45

α ₁-adrenergic receptors and Ca²⁺, **26**, 405

bi, mono-, triphosphate, metabolism in GH₃ pituitary tumor cells, **25**, 201

³H-labeled, metabolism in GH₃ pituitary tumor cells, **25**, 201

Interfacial phenomenon, **25**, 123

Intermolecular interactions, theoretical computations, **25**, 452

Intestine
 cytosol, 1,25-dihydroxyvitamin D₃ complexes (chicken), **25**, 86
 1,25-dihydroxyvitamin D₃-receptor complexes (chicken), **25**, 79
m-Iodobenzylguanidine, sodium-dependent uptake (bovine), **26**, 539

Iododeoxyuridine
 thymidine kinase-stimulated phosphorylation, **25**, 446

5-Iodo-5'-amino-2',5'-dideoxyuridine, stimulation of phosphorylation
 of thymidine, 5-iodo-2'-deoxyuridine, **25**, 446

Ion conduction
 cyclic AMP effects, **26**, 51
 nicotinic receptors, **26**, 51

Ion transport, effect of local anesthetics, **25**, 219

Ionic channel
 -acetylcholine receptor complex, **25**, 360, 384, 395
 alteration of kinetics, **25**, 92
 blockade, **25**, 384
 kinetics, **25**, 102
 -nicotinic acetylcholine receptor complex interactions with pyridostigmine, **25**, 92, 102

Insecticides
 hydrolysis, **26**, 99
 protein binding, **26**, 99

Insulin release, **26**, 267

Iproniazid metabolism, cytosolic effects, **26**, 566

Isoproterenol, forskolin-potentiated hormone response in C6-2B cells
 (rat), **25**, 256

Isozyme
 3a, cytochrome P-450, ethanol- and imidazole-induced (rabbit), **25**, 494
 6, cytochrome P-450, imidazol-induced (rabbit), **25**, 494

K

K⁺
 channel (crayfish), **25**, 369
 conductance, **26**, 267
 phosphorylation by, **26**, 141

KCl
 depolarization, effect in tracheal smooth muscle (dog), **25**, 267

Kidney
 porphyrin metabolism, **26**, 336
 uroporphyrinogen decarboxylase (rat), **26**, 336

Kinetics
 competitive radioligand binding, **25**, 1
 dual product formation, **25**, 467
 ionic channels, **25**, 102
 radioligand binding, prediction, **25**, 1
 sequential model, **26**, 293

L

L1210 clonogenic survival, **26**, 128

Leukemia cells, lethality of 5-methyl-2'-deoxycytidine (human), **25**, 431

Ligand-dye
 interactions with 1,25-dihydroxyvitamin D₃-receptor complexes (chicken), **25**, 79
 polyribonucleotide interaction (chicken), **25**, 86

Ligand selectivity, **25**, 343

Lipid methylation (mouse), **25**, 418

Lipoproteins, human plasma, and distribution of probucol, **26**, 322

Lithium, effect on [³H]inositol metabolism, GH₃ pituitary tumor cells, **25**, 201

Liver
 allyl alcohol metabolism (rat), **25**, 158
 cytochrome P-450, isozymes 3a and 6 (rabbit), **25**, 494
 distribution of folate (mouse), **25**, 459
 lobule, glucuronidation of 7-hydroxycoumarin (rat), **25**, 487
 5,10-methylenetetrahydrofolate reductase, effect of phenytoin treatment (mouse), **25**, 459
 peptide mapping (rabbit), **25**, 494
 periportal and pericentral zones (rat), **25**, 487

Lung, angiotensin-converting enzyme (rabbit), **25**, 287

Luteinizing hormone release (rat), **25**, 51

Lymphoma, S49 cells, *beta*-adrenergic receptors, **25**, 209

M

Mass action law, prediction of radioligand binding kinetics, **25**, 1

[³H]Mazindol, dopamine and norepinephrine uptake sites, **26**, 35

Membrane
 brain
 effect of ethanol, **25**, 410
 effect of pentobarbital, **25**, 410
 lipid composition (mouse), **25**, 401
 physical properties (mouse), **25**, 401
 chromaffin granule, reserpine binding (bovine), **25**, 113
 effect of local anesthetics, **26**, 314
 expansion, and inhalation anesthetics, **25**, 123
 fluidity
 effect of ethanol tolerance (mouse), **25**, 401
 ethanol effects, **25**, 410
 fluorescent probes (mouse), **25**, 401, **26**, 83
 muscle, interactions with phencyclidine (crayfish), **25**, 369
 phospholipid vesicle, **25**, 123
 stabilization, **25**, 123
 volume, and anesthesia, **25**, 123

Metabolism
 brown fat cell (hamster), **25**, 64
 carbon tetrachloride, reductive-oxygenation mechanism (rat), **25**, 318

Metabolism—*Continued*

- drug, extrahepatic, **25**, 185
- hepatic, allyl alcohol (rat), **25**, 158
- inositol, in GH₃ pituitary tumor cells, **25**, 201
- 5-methyl-2'-deoxycytidine, in leukemic cells (human), **25**, 431
- polycyclic aromatic hydrocarbon, in adrenal cortical cells (bovine), **25**, 476
- Metabolites, radical, binding to lipid, **26**, 112
- Methylation, lipid (mouse), **25**, 418
- 3-Methylcholanthrene, **26**, 117
- 5-Methyl-2'-deoxycytidine
 - deamination (human), **25**, 431
 - DNA exclusion (human), **25**, 431
 - effects on lethality in leukemic cells *in vitro* (human), **25**, 431
 - metabolism, in leukemic cells (human), **25**, 431
- 5,10-Methylenetetrahydrofolate reductase, hepatic, effect of phenytoin treatment (mouse), **25**, 459
- 5,11-Methenyltetrahydrohomofolate, inhibition of HKSV28 cell growth, **25**, 294
- Mg²⁺, Na⁺, **26**, 180
- Microaggregation, gonadotropin-releasing hormone (rat), **25**, 51
- Micro-light guide, NADH, **25**, 158
- Microsome, hepatic, cytochrome P-450 isozymes 3a and 6 (rabbit), **25**, 494
- Minor groove, (dA-dT)_n oligomers, **25**, 452
- Mitochondria, monoamine oxidase topography, **25**, 165
- Mitoxantrone
 - antitumor activity, **25**, 178
 - binding to DNA, **25**, 178
- Molecular electrostatic potential maps, **26**, 19
- Molecular modulators, receptor affinity, activity, **26**, 19
- Monoamine oxidase
 - multiple forms, **25**, 165
 - topography, **25**, 165
- Monooxygenase
 - activity of hemoglobin, substrate specificity, **25**, 467
 - N- and O-demethylation, **25**, 467
 - p-hydroxylation, **25**, 467
 - regioselective metabolism, **25**, 467
- Morphine, *mu*₁ binding sites, **25**, 29
- Muscarinic agonists, **26**, 149
- Muscarinic receptors, regulation, **26**, 156
- Muscle
 - interosseal (frog), **25**, 102
 - membranes, interactions with phencyclidine (crayfish), **25**, 369
 - skeletal
 - effect of amiloride (chick), **25**, 131
 - glucocorticoid receptor (rat), **25**, 70
 - vertebrate, **26**, 45
 - twitch
 - alteration by pyridostigmine, **25**, 92
 - blockade by gephyrotoxin, **25**, 384
- Mutant, neurological (mouse), **25**, 24
- Myoball, neonatal (rat), **25**, 102
- Myosin light chain, phosphorylation in tracheal smooth muscle (bovine), **25**, 267

N

- Na⁺
 - dependency, [³H]norepinephrine release (rat), **25**, 379
 - channels, tetrodotoxin-resistant interaction, polypeptide neurotoxins (rat), **26**, 70
 - /H⁺ exchange system, **25**, 131
- NADH, micro-light guide, **25**, 158
- NADPH supply, periportal and pericentral regions (rat), **26**, 574
- Nafazatrom, prostacyclin stimulation, **26**, 328
- [³H]Naloxonazine binding, rat brain membranes, **26**, 477

- Naloxone, *in vivo* receptor binding (rat), **25**, 242
- Neonate myoballs (rat), **25**, 102
- Neuroblastoma cells
 - culturing, **26**, 156
 - voltage-sensitive sodium channels, **25**, 228
- Neurological mutant (mouse), **25**, 24
- Neuromuscular transmission, effect of gephyrotoxin, **25**, 395
- Neurones, locus coeruleus, opiate-receptor interactions, **26**, 489
- Neurotoxin
 - effect on sodium channels, **25**, 219, 228
 - sea anemone and scorpion, interaction with tetrodotoxin-resistant Na⁺ channels (rat), **26**, 70
- Nicotinic receptor cyclic AMP effects, **26**, 51
- Nitrendipine, ³H-labeled, heterogeneity of binding sites, **25**, 235
- p-Nitrosophenetole, reaction with glutathione, **26**, 342
- NMR, deuterium of anesthetics, **26**, 314
- Noise analysis, acetylcholine, **25**, 384
- Norepinephrine
 - binding in vas deferens (rat), **25**, 56
 - palytoxin-induced (rat), **25**, 379
 - ³H-labeled, release
 - Ca²⁺ and Na⁺ dependency (rat), **25**, 379
 - uptake
 - inhibition, **26**, 35
 - sodium and chloride dependency, **26**, 35
 - sodium-dependent (bovine), **26**, 539
- Novonal
 - cytochrome P-450 destruction (rat), **25**, 310
 - prosthetic heme adducts (rat), **25**, 310
- Nuclear magnetic resonance
 - interaction of avoparcin with receptor of cell wall, **25**, 281
 - studies on antibiotic, avoparcin, **25**, 275
 - guanine, effect on D₂-dopamine receptors in brain (calf), **25**, 10
 - guanyl, regulation, solubilized vasopressin receptors (rat), **26**, 241

O

- O₂, miniature electrode, **25**, 158
- Oligomer, double-stranded (dA-dT)_n, nonintercalative binding of berenil and stilbamidine, **25**, 452
- Oocyte adenylate cyclase, progesterone inhibition, **26**, 526
- Opiate, *mu*₁ binding sites, **25**, 29
- Opiate receptor
 - adrenal medullary (bovine), **25**, 38
 - high-affinity binding, **25**, 29
 - in pheochromocytoma (human), **25**, 38
 - interactions, single locus coeruleus neurones, **26**, 489
- Opioid
 - binding sites
 - biochemical characterization, by [³H]naloxonazine (rat), **26**, 477
 - brain (guinea pig), **25**, 337
 - brain (rat), **25**, 242
 - delta* subclass, selective inhibition, **25**, 249
 - mu*₁, **25**, 29
 - ³H-labeled, high-affinity binding, biochemical characterization, **25**, 29
 - receptor
 - binding *in vivo* (rat), **25**, 242
 - binding selectivity, **25**, 337
 - characterization, **25**, 38
 - ileum (guinea pig), **25**, 343
 - multiple (guinea pig), **25**, 343
 - multiplicity (rat), **25**, 242
 - pharmacological selectivity, **25**, 343
 - selective ligands, **25**, 337
 - site-directed alkylation, **25**, 337, 343
 - vas deferens (mouse), **25**, 343
- Organophosphate pesticide disposition, **26**, 99

- Oxidation**
 mixed function, liver, normal and phenobarbital-treated (rat), **26**, 574
 organosulfur compounds, **26**, 348
 Oxotremorine derivative, 2-chloroalkylamine, **26**, 170
 Oxygen dependency, carbon tetrachloride metabolism (rat), **25**, 318
 Oxygen radicals, **26**, 360
 Oxygenation
 reductive, carbon tetrachloride (rat), **25**, 318
 trichloromethyl radical (rat), **25**, 318
- P**
- Palytoxin**
⁴⁵Ca flux (rat), **25**, 379
²²Na influx (rat), **25**, 379
 [³H]norepinephrine release (rat), **25**, 379
 pheochromocytoma cell line (rat), **25**, 379
 Pancreatic islets, **26**, 267
 Patch clamp
 cultured muscle cells (rat), **26**, 304
 single channels, **25**, 102
 pBR322, plasma, drug binding to, **25**, 178
 PC12 cells, **26**, 51, 141
 Pentobarbital, membrane action, effect of gangliosides, **25**, 410
 Pentylene tetrazol, **26**, 83
 Peptide
 -avoparcin complexes, structure, **25**, 275
 maps, hepatic isozyme (rabbit), **25**, 494
 secretion, apomorphine enantiomers (carp, rat), **25**, 18
 Perhydrohistriocotoxin, binding inhibition, **25**, 395
 Peroxidase, covalent binding, **26**, 105
 Phenacetin metabolites, reaction with glutathione and DNA, **26**, 342
 Phencyclidine
 binding
 to acetylcholine receptor (ray), **25**, 360
 inhibition by Ca²⁺ antagonists (crayfish), **25**, 369
 to muscle (crayfish), **25**, 369
 interactions with muscle membranes (crayfish), **25**, 369
 p-Phenetidine, reaction with glutathione, **26**, 342
 Phenol, hydroquinone, **26**, 105
 [³H]Phenoxybenzamine binding, **26**, 196
 Phenytoin
 chronic treatment, effect on hepatic 5,10-methylenetetrahydrofolate reductase activity (mouse), **25**, 459
 folate biochemistry (mouse), **25**, 459
 Pheochromocytoma
 [³H]norepinephrine release (rat), **25**, 379
 opiate receptors (human), **25**, 38
 Phorbol (di)esters, **26**, 261
 Phosgene, derivation from carbon tetrachloride in liver microsomes (rat), **25**, 318
 Phosphatidic acid, accumulation in GH₃ pituitary tumor cells, **25**, 193
 Phosphatidylinositol
 α₁-adrenergic receptors and Ca²⁺, **26**, 405
 turnover, **26**, 149, 267
 in brown fat cells (hamster), **25**, 64
 Phosphatidylinositol 4-phosphate in GH₃ pituitary tumor cells, effect of thyrotropin-releasing hormone, **25**, 193, 201
 Phosphatidylinositol 4,5-bisphosphate effect of thyrotropin-releasing hormone, **25**, 193
 in GH₃ pituitary tumor cells, effect of thyrotropin-releasing hormone, **25**, 193, 201
 Phosphodiesterase, inhibition in thyroid (dog), **25**, 261
 Phospholipase C
 role in thyrotropin-releasing hormone action in pituitary tumor cells, **25**, 193, 201
 Phospholipid
 brain, ethanol effects (mouse), **25**, 401
 vesicle membrane, **25**, 123
 Phosphorylase phosphorylation in tracheal smooth muscle (dog), **25**, 267
 Phosphorylation
 by 46 mM K⁺, **26**, 141
 myosin light chain and phosphorylase in tracheal smooth muscle (bovine), **25**, 267
 Photoaffinity cross-linking, **26**, 187
 [³H]Pirenzepine, **26**, 164
 Pituitary
 anterior, **26**, 214
 platelet, adipocytes, liver membranes, GTP, **26**, 180
 GH₃ tumor cells
 effect of thyrotropin-releasing hormone, **25**, 193
 [³H]inositol metabolism, **25**, 201
 phosphatidylinositol 4-phosphate, **25**, 193
 phosphatidylinositol 4,5-bisphosphate, **25**, 193
 intermediate lobe, multiple dopamine receptors (rat), **25**, 18
 Placenta, aldose reductase (human), **25**, 425
 PM2, circular DNA, drug binding to, **25**, 178
 Polycyclic aromatic hydrocarbon
 metabolism in adrenal cortical cells (bovine), **25**, 476
 steroidogenesis in adrenal cortical cells (bovine), **25**, 476
 Poly(G), dye-ligand interactions, **25**, 79
 Poly(I), dye-ligand interactions, **25**, 79
 Polyphosphoinositide, breakdown in GH₃ pituitary tumor cells, **25**, 201
 Polynucleotide binding in intestinal cytosol (chicken), **25**, 86
 Potentiation
 hormone response in C6-2B cells (rat), **25**, 256
 substance P activity *in vivo* by captopril and MK-422 (rabbit), **25**, 287
 Prazosin
 effect on phosphatidylinositol metabolism (hamster), **25**, 64
³H-labeled binding, **26**, 196
 Probe, radioiodinated high affinity, **26**, 187
 Probucol, in human plasma lipoproteins, **26**, 322
 Proenkephalin mRNA, modulation, **26**, 255
 Progesterone, inhibition, *Xenopus* oocyte adenylate cyclase, **26**, 526
 Prolactin synthesis, estrogen-stimulated, **26**, 279
 Prostacyclin synthase, protection, **26**, 328
 Prostaglandin H synthase, stimulation by nafazatrom, **26**, 328
 Protease
 effect on γ-aminobutyric acid binding in brain (rat), **25**, 352
 probe of mitochondrial monoamine oxidase topography *in situ*, **25**, 165
 Protein
 carboxymethylation (mouse), **25**, 418
 carcinogen-binding, **26**, 353
 islet-activating, *Bordetella pertussis*, and progesterone inhibition, **26**, 526
 regulatory for hormone receptors, **26**, 214
 Protein kinase C
 and phorbol ester, 12-*O*-tetradecanoylphorbol-13-acetate, **26**, 267
 role in secretion, **26**, 261
 Proteolysis, receptor, **25**, 79
 Pseudocholinesterase molecular forms, **26**, 45
 Purification
 bungarotoxin polypeptide, **25**, 327
 liver microsomal cytochrome P-450 isozymes 3a and 6 (rabbit), **25**, 494
 Purine
 biosynthesis
 glycinamide transformylase, **25**, 294
 inhibition of homofolic acid derivatives, **25**, 294
 nucleotide specificity, **26**, 369
 Pyridostigmine
 agonist properties, **25**, 92

Pyridostigmine—*Continued*

- alteration of end-plate currents, **25**, 92
- anticholinesterase agent, **25**, 92
- interactions with the nicotinic acetylcholine receptor-ionic channel complex, **25**, 92

Q

- [³H]Quinuclidinyl benzilate, **26**, 164
- Quinone-containing antitumor agents, **26**, 582

R

Radiation

- inactivation, **26**, 196

Radical metabolites, binding to lipid, **26**, 112

Radioligand

- binding
 - kinetics, **25**, 1
 - mixed stereoisomer, **26**, 414
 - prediction, **25**, 1
 - thermodynamics, **26**, 1

Receptor

acetylcholine

- ionic channel complex, **25**, 384, 395
- nicotinic, **26**, 51
- phencyclidine binding (rat), **25**, 360

adenosine, brain, **26**, 1

- adrenergic, *see* Adrenergic receptor

agonist

- induced changes, **25**, 209
- states in brain (calf), **25**, 10

 α_1 -adrenergic

- Ca²⁺ and phosphatidylinositol, **26**, 405
- structure, **26**, 196

 β -adrenergic, synthesis, human astrocytoma cells, **26**, 424 γ -aminobutyric acid inhibitory cyclase (rat), **25**, 24aryl hydrocarbon, **26**, 353avoparcin, bacterial cell wall, **25**, 281benzodiazepine, **26**, 228

- interactions, zopiclone and suriclone, **26**, 458

binding, **26**, 156, 484

- 16 α ,17 α -acetal-substituted glucocorticoids, **25**, 70

cholinergic, phencyclidine binding (rat), **25**, 360for cytochrome P-450 induction, **26**, 117cytosolic, for 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, **26**, 90-1,25-dihydroxyvitamin D₃ complexes dye-ligand interactions (chicken), **25**, 79, 86-1,25-dihydroxyvitamin D₃ complexes in intestinal cytosol (chicken), **25**, 86dimers, **26**, 196dopamine, **26**, 214

- D₂, in brain (calf), **25**, 10

- D₂, characterization with aminotetralins, **26**, 452

- multiple (carp, rat), **25**, 18

dopaminergic, and [³H]dopamine sites, distinctions, **26**, 439down-regulation (rat), **25**, 51, **26**, 206-effector coupling, **26**, 214estrogen, **26**, 279glucocorticoid, ligand structure, skeletal muscle (rat), **25**, 70 α_1 , hepatic (rat), **26**, 187heterogeneity, **26**, 228hormone, regulatory proteins for, **26**, 214isomerization, **26**, 164limited proteolysis of, **26**, 196

muscarinic

- binding of tertiary amines, **25**, 46
- cholinergic, **26**, 149, 164
- cyclic AMP metabolism, **26**, 395

guinea pig ileum, **26**, 170irreversible binding, **26**, 170regulation, **26**, 156molecular weights, **26**, 196

nicotinic acetylcholine

- in adrenal chromaffin cells, **25**, 327

- ionic channel complex, **25**, 92, 102

- phencyclidine binding (rat), **25**, 360

neuromuscular junction, **26**, 293nonequilibrium studies, **25**, 209

opiate

- adrenal medullary (bovine), **25**, 38

- high-affinity binding, **25**, 29

- in pheochromocytoma (human), **25**, 38

opioid

- binding *in vivo* (rat), **25**, 242

- binding selectivity, **25**, 337

- ileum (guinea pig), **25**, 343

- multiplicity (rat), **25**, 242

- pharmacological selectivity, **25**, 343

- selective ligands, **25**, 337

- site-directed alkylation, **25**, 337, 343

- vas deferens (mouse), **25**, 343

peripheral nicotinic, myoballs, **26**, 304proteolysis, **25**, 79purification, **26**, 196-receptor interactions (rat), **25**, 51regulation of gonadotropin release (rat), **25**, 51 α_1 , splenic (rat), **26**, 187subtypes, **26**, 164topology, **26**, 196up-regulation (rat), **25**, 51vasopressin, solubilized, two molecular forms (rat), **26**, 241Receptor-effector coupling, angiotensin-induced (bovine), **26**, 498Reduction, N-acetyl-*p*-benzoquinone imine, **25**, 151Reductive oxygenation, carbon tetrachloride, by cytochrome P-450 (rat), **25**, 318

Reserpine

binding

- to chromaffin granule membranes (bovine), **25**, 113

- comparison with dihydrotetrabenazine binding (bovine), **25**, 113

RNA

- covalent binding, **26**, 369

- processing, **26**, 135

- ribosomal, **26**, 135

mRNA induction, turnover, **26**, 117RNase III, **26**, 135[³H]Ro 22-1319 (piquindone) binding to D₂ receptor subtype (rat), **26**, 430

S

Secretion

- peptide, apomorphine enantiomers (carp, rat), **25**, 18

- role of protein kinase C in, **26**, 261

Semiempirical molecular orbital methods, **26**, 19

Sensitivity

acetylcholine

- extrajunctional region, **25**, 395

- junctional region, **25**, 395

phencyclidine, to calcium channel antagonists (crayfish), **25**, 369Skeletal muscle, vertebrate, **26**, 45Smooth muscle, α_1 -adrenergic receptors (rat), **25**, 56

Sodium

- channels, [³H]batrachotoxinin A 20- α -benzoate binding, **25**, 219

- dependent uptake, *m*-iodobenzylguanidine and norepinephrine, **26**, 539

- [³H]Ro 22-1319 (piquindone) binding to D₂ receptor subtype, **26**, 430

voltage-sensitive channels, inhibition in neuroblastoma cells and synaptosomes, **25**, 228
 Sodium dodecyl sulfate gel electrophoresis, **26**, 196
 Sodium valproate, comparison, ethanol (mice), **26**, 547
 Sorbinil, inhibition of placenta aldose reductase (human), **25**, 425
 Spiroperidol
 binding
 in brain (calf), **25**, 10
 to D₂ dopaminergic receptors (rat), **26**, 439
 Steroidogenesis, polycyclic aromatic hydrocarbon in adrenal cortical cells (bovine), **25**, 476
 Stilbamidine, nonintercalative binding, **25**, 452
 Stimulus-secretion coupling, **26**, 261
 Stoichiometry
 binding
 theory, **25**, 137
 versus site-oriented analysis, **25**, 137
 Structure-activity relationship, amiloride, **25**, 131
 Structure, 16 α ,17 α -acetyl-substituted glucocorticoids, **25**, 70
 Substance P
 carboxyl-terminal tripeptidyl hydrolysis, **25**, 287
 degradation by angiotensin-converting enzyme (rabbit), **25**, 287
 potentiation *in vivo* by captopril and NK-422 (rabbit), **25**, 287
 substrate for angiotensin-converting enzyme (rabbit), **25**, 287
 Sufentanil, *in vivo* receptor binding (rat), **25**, 242
 Sulfonylurea, **26**, 267
 Suriclone and zopiclone binding, benzodiazepine receptors, **26**, 458
 Synaptosome, voltage-sensitive sodium channels, **25**, 228

T

Tachykinin binding sites, **26**, 248
 Tamoxifen, effect on estrogen receptor binding activity, **26**, 272
 Target size analysis, **26**, 96
 Ternary complex, agonist binding, **26**, 10
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin, **26**, 90, 117
 12-*O*-Tetradecanoylphorbol-13 acetate, **26**, 267
 Thiol reagents, inhibition of erythrocyte sickling, **26**, 559
 Thiourea metabolism, **26**, 122
 Thymidine
 analogue
 antineoplastic activity, **25**, 441
 cytotoxicity, **25**, 446
 phosphorylation, **25**, 446
 kinase
 -stimulated phosphorylation of iododeoxyuridine, **25**, 446
 -stimulated phosphorylation of thymidine, **25**, 446
 viral, **26**, 376
 Thymidylate synthase
 inhibition by 5-fluorouracil, **25**, 303
 levels in cells exposed to 5-fluorouracil, **25**, 171
 Thyroid, cyclic AMP accumulation, effects of xanthines (dog), **25**, 261
 Thyrotropin-releasing hormone
 effect on GH₃ pituitary tumor cells, **25**, 193
 -stimulated [³H]inositol metabolism in GH₃ pituitary tumor cells, **25**, 201
 Tetrabenazine binding in chromaffin granule membranes (bovine), **25**, 113
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin induction of cytochrome P-450, **25**, 185
 Toxicity, *see also* Hepatotoxicity
 allyl alcohol (rat), **25**, 158

and glutathione, **26**, 342
 phenytoin (mouse), **25**, 459
 Transcriptional activation, **26**, 117
 Transmethylation, *S*-adenosylmethionine-dependent effects of adenosine dialdehyde (mouse), **25**, 418
 Transport ion, effect of local anesthetics, **25**, 219
 Trichloromethylperoxyl radical decomposition to phosgene (rat), **25**, 318
 Trichloromethyl radical oxygenation (rat), **25**, 318
 Tripeptidyl hydrolysis, substance P, **25**, 287
 Tumor
 pituitary GH₃
 effect of thyrotropin-releasing hormone, **25**, 193
 [³H]inositol metabolism, **25**, 201
 Tyrosine hydroxylase, activation, **26**, 141

U

Ultraviolet, DNA damage, **25**, 322
 Uptake
 catecholamine
 in chromaffin granule membranes (bovine), **25**, 113
 dopamine and norepinephrine
 inhibition, **26**, 35
 sodium and chloride dependency, **26**, 35
 Uroporphyrinogen decarboxylase
 metal inhibition, mercury, **26**, 336
 GSH stimulation, **26**, 336

V

Valproic acid, **26**, 83
 Varicella zoster virus, **26**, 376
 Vasopressin receptors, two molecular forms, rat kidney membranes, **26**, 241
 Vero cells, Herpes simplex-infected, metabolic effect of FIAC, **26**, 587
 Voltage-sensitive sodium channels in neuroblastoma cells and synaptosomes, **25**, 228
 Verapamil inhibition of [³H]phencyclidine binding (crayfish), **25**, 369
 Volume
 mean excess, anesthesia hypothesis, **25**, 123
 molal, partial, **25**, 123
 Vas deferens
 α ₁-adrenergic receptors (rat), **25**, 56
 ¹²⁵I-BE 2254 binding (rat), **25**, 56
 norepinephrine binding (rat), **25**, 56
 radioligand binding (rat), **25**, 56

X


Xanthine
 alkylated, effects on cyclic AMP accumulation in thyroid (dog), **25**, 261
 derivatives, effects on thyroid (dog), **25**, 256

Y

Yohimbine, effect on phosphatidylinositol metabolism (hamster), **25**, 64

Z

Zopiclone and suriclone binding, benzodiazepine receptors, **26**, 458

U.S. Postal Service STATEMENT OF OWNERSHIP, MANAGEMENT AND CIRCULATION <small>Required by 39 U.S.C. 3685</small>		
1A. TITLE OF PUBLICATION MOLECULAR PHARMACOLOGY	1B. PUBLICATION NO. 0 0 2 6 8 9 5 X	2. DATE OF FILING 10/1/84
3. FREQUENCY OF ISSUE Bi-monthly	3A. NO. OF ISSUES PUBLISHED ANNUALLY 6	3B. ANNUAL SUBSCRIPTION PRICE \$75.00
4. COMPLETE MAILING ADDRESS OF KNOWN OFFICE OF PUBLICATION (Street, City, County, State and ZIP Code) (Not printers)		
428 East Preston Street, Baltimore, MD 21202		
5. COMPLETE MAILING ADDRESS OF THE HEADQUARTERS OF GENERAL BUSINESS OFFICES OF THE PUBLISHER (Not printers)		
428 East Preston Street, Baltimore, MD 21202		
6. FULL NAMES AND COMPLETE MAILING ADDRESS OF PUBLISHER, EDITOR, AND MANAGING EDITOR (This item MUST NOT be blank)		
PUBLISHER (Name and Complete Mailing Address) Williams & Wilkins, 428 E. Preston St., Baltimore, MD 21202		
EDITOR (Name and Complete Mailing Address) Dr. Joel Hardman, Department of Pharmacology, Vanderbilt University, Medical Center, Nashville, TN 37232		
MANAGING EDITOR (Name and Complete Mailing Address)		
7. OWNER (If owned by a corporation, its name and address must be stated and also immediately thereunder the names and addresses of stockholders owning or holding 1 percent or more of total amount of stock. If not owned by a corporation, the names and addresses of the individual owners must be given. If owned by a partnership or other unincorporated firm, its name and address, as well as that of each individual must be given. If the publication is published by a nonprofit organization, its name and address must be stated.) (Form must be completed.)		
FULL NAME American Society for Pharmacology and Experimental Therapeutics		
COMPLETE MAILING ADDRESS 9650 Rockville Pike Bethesda, MD 20814		
8. KNOWN BONDHOLDERS, MORTGAGEES, AND OTHER SECURITY HOLDERS OWNING OR HOLDING 1 PERCENT OR MORE OF TOTAL AMOUNT OF BONDS, MORTGAGES OR OTHER SECURITIES (If there are none, so state)		
FULL NAME NONE		
COMPLETE MAILING ADDRESS		
9. FOR COMPLETION BY NONPROFIT ORGANIZATIONS AUTHORIZED TO MAIL AT SPECIAL RATES (Section 433.12 DMM only) The purpose, function, and nonprofit status of this organization and the exempt status for Federal income tax purposes (Check one)		
(1) <input checked="" type="checkbox"/> HAS NOT CHANGED DURING PRECEDING 12 MONTHS		
(2) <input type="checkbox"/> HAS CHANGED DURING PRECEDING 12 MONTHS (If changed, publisher must submit explanation of change with this statement.)		
10. EXTENT AND NATURE OF CIRCULATION (See instructions on reverse side)		
A. TOTAL NO. COPIES (Net Press Run)	AVERAGE NO. COPIES EACH ISSUE DURING PRECEDING 12 MONTHS 2400	ACTUAL NO. COPIES OF SINGLE ISSUE PUBLISHED NEAREST TO FILING DATE 2700
B. PAID AND/OR REQUESTED CIRCULATION	NONE	NONE
1. Sales through dealers and carrier, street vendors and counter sales		
2. Mail Subscriptions (Paid and/or requested)	1547	1396
C. TOTAL PAID AND/OR REQUESTED CIRCULATION (Sum of 1B1 and 1B2)	1547	1396
D. FREE DISTRIBUTION BY MAIL, CARRIER OR OTHER MEANS SAMPLES, COMPLIMENTARY, AND OTHER FREE COPIES	71	81
E. TOTAL DISTRIBUTION (Sum of C and D)	1618	1477
F. COPIES NOT DISTRIBUTED		
1. Office use, left over, unsolicited, mailed after printing	782	1223
2. Return from News Agents	NONE	NONE
G. TOTAL (Sum of E, F1 and 2—should equal net press run shown in A)	2400	2700
11. I certify that the statements made by me above are correct and complete		
SIGNATURE AND TITLE OF EDITOR, PUBLISHER, BUSINESS MANAGER, OR OWNER 		Publisher

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: stereochemical, electronic, and other parameters of drug architecture; conformational analysis of receptors and their function; drug-enzyme and other interactions between drugs and macromolecules; drug effects upon gene replication and transcription and on protein synthesis; mechanism of action of antibiotics and other growth-inhibitory drugs; induction by drugs of changes in macromolecular structure or allosteric transitions; drug-induced alterations in metabolic pathways; effects of hormones and other drugs on cellular regulatory mechanisms; chemical mutagenesis, carcinogenesis, and teratogenesis; pharmacogenetics, idiosyncrasies, and drug allergies; selective toxicity in a single organism or in different species; drug actions on properties and functions of membranes; mechanisms of drug metabolism; distribution and transport of drug molecules between biological compartments.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to Dr. Joel Hardman, Editor, *Molecular Pharmacology*, Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, U. S. A.

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds payable to ASPET) or by a validated purchase order from the authors' institution. The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 259, pp. 1-11, January 10, 1984). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that

have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text, including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baucé, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Sandler, M. Variations in monoamine oxidase activity in some human disease states, in *Monoamine Oxidase and Its Inhibition*. Ciba Foundation Symposium 39. Elsevier, Amsterdam, 327-340 (1976). (7). Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should

appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (\times , \circ , \bullet , \square , \blacksquare , \triangle , \blacktriangle , \odot). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Galley proof. The cost of all changes on galley proof, other than printer's errors, will be charged to authors. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Acting Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.